4//SEC Filing
Treco Douglas A 4
Accession 0000950170-25-050443
CIK 0001693011other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 4:27 PM ET
Size
9.1 KB
Accession
0000950170-25-050443
Insider Transaction Report
Form 4
Treco Douglas A
DirectorCEO & Chairman
Transactions
- Exercise/Conversion
Common Stock
2025-04-01+25,000→ 49,865 total - Sale
Common Stock
2025-04-02$0.89/sh−8,819$7,849→ 41,046 total - Exercise/Conversion
Restricted Stock Units
2025-04-01−25,000→ 50,000 total→ Common Stock (25,000 underlying)
Footnotes (4)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
- [F2]Includes 2,490 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 31, 2025.
- [F3]This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person.
- [F4]On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
Related Parties
1- filerCIK 0001688192
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 4:27 PM ET
- Size
- 9.1 KB